BioSyent Inc.
RX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.28M | 7.01M | 6.54M | 5.74M | 6.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.28M | 7.01M | 6.54M | 5.74M | 6.08M |
| Cost of Revenue | 1.17M | 1.52M | 1.37M | 1.18M | 1.15M |
| Gross Profit | 5.11M | 5.49M | 5.17M | 4.56M | 4.93M |
| SG&A Expenses | 7.05M | 3.49M | 3.76M | 3.01M | 3.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.40M | 5.00M | 5.13M | 4.19M | 4.96M |
| Operating Income | 3.17M | 2.00M | 1.41M | 1.55M | 1.12M |
| Income Before Tax | 1.61M | 2.18M | 1.57M | 1.78M | 1.36M |
| Income Tax Expenses | 455.60K | 489.20K | 416.40K | 473.00K | 296.90K |
| Earnings from Continuing Operations | 1.15M | 1.69M | 1.15M | 1.31M | 1.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.15M | 1.69M | 1.15M | 1.31M | 1.07M |
| EBIT | 3.17M | 2.00M | 1.41M | 1.55M | 1.12M |
| EBITDA | 3.56M | 2.06M | 1.47M | 1.61M | 1.18M |
| EPS Basic | 0.10 | 0.15 | 0.10 | 0.11 | 0.09 |
| Normalized Basic EPS | 0.19 | 0.12 | 0.08 | 0.10 | 0.07 |
| EPS Diluted | 0.10 | 0.14 | 0.10 | 0.11 | 0.09 |
| Normalized Diluted EPS | 0.19 | 0.12 | 0.08 | 0.09 | 0.07 |
| Average Basic Shares Outstanding | 11.50M | 11.59M | 11.59M | 11.67M | 11.80M |
| Average Diluted Shares Outstanding | 11.71M | 11.82M | 11.80M | 11.87M | 12.01M |
| Dividend Per Share | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Payout Ratio | 31.79% | 22.59% | 32.99% | 29.63% | 32.55% |
